期刊文献+

钙剂在肾脏疾病中的应用 被引量:1

原文传递
导出
摘要 在组成人体的元素中,钙仅次于氧、碳、氢和氮元素,位居第5位,其在人体中的含量占人体重的1.9%。体内99%的钙用于形成骨骼。另有0.6%的钙用于生成牙齿,软组织中有0.6%.血浆中含钙0.03%,血管外液中仅有0.06%。故人体内的钙可以分为3部分:骨骼内的钙,细胞外液内的钙(受甲状旁腺激素和维生素D调节),细胞内的钙。约有1%的骨钙可以自由地与细胞内外液进行交换.从而缓冲血浆中钙离子的变化。
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2006年第11期709-712,共4页 Chinese Journal of Nephrology
  • 相关文献

参考文献43

  • 1Nordin BE.Calcium and osteoporosis.Nutrition,1997,13:664-686.
  • 2黄雯.钙磷代谢及肾脏对钙磷平衡的调节[J].中国血液净化,2004,3(4):175-177. 被引量:18
  • 3Hruska KA,Teitelbaum SL.Renal osteodystrophy.N Engl J Med,1995,333:166-174.
  • 4Alem AM,Sherrard DJ,Gillen DL,et al.Increased risk of hip fracture among patients with end-stage renal disease.Kidney Int,2000,58:396-399.
  • 5Spasovski GB,Bervoets AR,Behets GJ,et al.Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis.Nephrol Dial Transplant,2003,18:1159-1166.
  • 6Aparicio M,Combe C,Lafage MH,et al.In advanced renal failure,dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol.Nephron,1993,63:122-123.
  • 7范敏华.腹膜透析钙磷代谢[J].中国血液净化,2004,3(12):639-642. 被引量:4
  • 8Malluche H,Faugere MC.Renal bone disease 1990:an unmet challenge for the nephrologist.Kidney Int,1990,38:193-211.
  • 9Sherrard DJ,Hercz G,Pei Y,et al.The spectrum of bone disease in end-stage renal failure-an evolving disorder.Kidney Int,1993,43:436-442.
  • 10Locatelli F,Cannata-Andia JB,Drueke TB,et al.Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency,with emphasis on the control of hyperphosphataemia.Nephrol Dial Transplant,2002,17:723-731.

二级参考文献14

  • 1韩庆烽,史均宝,范敏华.腹膜透析患者的钙磷代谢紊乱及其影响因素[J].中国血液净化,2002,1(12):4-6. 被引量:11
  • 2林善琰主编.当代肾脏病学[M].上海: 上海科技教育出版社,2001,9.286-289,775-777.
  • 3[5]Malluche H,Faugere M,Renal bone disease. an unmet challenge for the nephrologists. Kidny Int, 1990,38:193 - 211
  • 4[6]Sherrard D,Hercz G,Pei Y, et al. The spectrum of bone disease in end - stage renal failure - an evolving disorder kidney Int, 1993,43:436 -442
  • 5[7]Block, GA, Sakiewicz PG. Serum bicarbonate levels with sevelamer versus calcium containing phosphate binders in hemodialysis patients. Presented at ASN/ISN World Congress of Nephrology, San Francisco, CA,2001
  • 6[8]Kuster S,Ritz E,Horl W. A role for metabolic acidosis in the genesis of renal secondary hyperparathyroidism. 1n: Israel Eliahou H, Iaina A, Bar- Khayim Y,eds. Abstract Book, Ⅻ th Intenational Congress of Nephrology, Jerusalem, 1993,p.467
  • 7[9]Delmez J, Slatopolsky E, Martin K, et al. Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int, 1982,21:862
  • 8[10]Chaefer K, Umlauf E, Von Herrath D, Reduced risk of hypercalcaemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis, 1992,19:460-464
  • 9[11]Sukamoto Y,Nomura M, Takahashi Y, et al. The oral 1.25- dihydroxyvitamin D3 pulse therapy in hemodialysis patients with severe secondary hyperparathyroidism. Nephron, 1991,57:23-28
  • 10[2]Blumenkrantz M, Kopple J, Moran J, et al. Metabolic balance studies and dietary protein requirements in patients undergoing CAPD. Kidney Int,1982,21:849 - 851

共引文献20

同被引文献11

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部